Vaxart Inc
Change company Symbol lookup
Select an option...
VXRT Vaxart Inc
CIHHF China Merchants Bank Co Ltd
BBY Best Buy Co Inc
BDGE Bridge Bancorp Inc
FFIC Flushing Financial Corp
TSC TriState Capital Holdings Inc
CSQPF Cervus Equipment Corp
IMXI International Money Express Inc
MDCO Medicines Co
TVETF Traverse Energy Ltd
Go

Health Care : Biotechnology | Small Cap ValueCompany profile

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Closing Price
$2.13
Day's Change
0.045 (2.16%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.35
Day's Low
2.00
Volume
(Light)
Volume:
493,028

10-day average volume:
3,555,464
493,028

Macy's stock plunges after profit and sales outlook slashed

8:17 am ET January 10, 2019 (MarketWatch)
Print

Shares of Macy's Inc. (M) plunged 17% in premarket trade Thursday, after the department store chain slashed its outlook for profit, sales and gross margin, citing a weakening in sales in late-December. The company reported holiday-period same-store sales growth of 0.7%, compared with 1.0% growth in the same period a year ago. Macy's cut its fiscal 2018 same-store sales growth outlook to approximately 2.0% from 2.3% to 2.55; its net sales outlook to approximately flat from up 0.3% to up 0.7%; its gross margin rate guidance to "down slightly" from "up slightly"; its inventory position to "no change" from "down;" and its adjusted earnings-per-share projection to $3.95 to $4.00 from $4.10 to $4.30, compared with the FactSet consensus of $4.23. "The holiday season began strong - particularly during Black Friday and the following Cyber Week, but weakened in the mid-December period and did not return to expected patterns until the week of Christmas," said Chief Executive Jeff Gennette. He said underperformance in women's sportswear, seasonal sleepwear, fashion jewlery and watches and cosmetics offset strength in fine jewelry, women's shoes, fragrance, dresses, outerwear, active and home. The stock has lost 3.2% over the past three months through Wednesday, while the SPDR S&P Retail ETF (XRT) has declined 6.1% and the Dow Jones Industrial Average has shed 6.7%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

January 10, 2019 08:17 ET (13:17 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.